中危主动脉瓣狭窄合并冠心病:完全经皮 vs 外科主动脉瓣置换加血运重建的随机对照研究
SURTAVI 试验纳入 1660 例中危重度主动脉瓣狭窄患者,其中 332 例因冠心病需血运重建,随机接受 TAVR+PCI 或 SAVR+CABG。2 年全因死亡或致残性卒中率在两种策略间无显著差异(16.0% vs 14.0%,P=0.62),TAVR 与 SAVR 整体亦无差异(11.9% vs 12.3%,P=0.76)。
要点
- 中危重度主动脉瓣狭窄合并非复杂冠心病(SYNTAX≤22)者,TAVR+PCI 可作为 SAVR+CABG 的合理替代。
- 需血运重建亚组 2 年全因死亡或致残性卒中率 TAVR+PCI 16.0% vs SAVR+CABG 14.0%,无统计学差异。
- 整体队列 TAVR 与 SAVR 的 2 年主要终点率分别为 11.9% 与 12.3%,亦无显著差异。
核心结论
- 对于中危重度主动脉瓣狭窄合并非复杂冠心病(SYNTAX 评分≤22)的患者,完全经皮 TAVR+PCI 策略是 SAVR+CABG 的合理替代方案。
研究设计与样本
- SURTAVI 前瞻性随机试验,2012 年 6 月至 2016 年 6 月在美国、加拿大和欧洲 87 家中心纳入中危重度主动脉瓣狭窄患者。
- 共 1660 例尝试植入主动脉瓣,其中 332 例(20%)按需血运重建分层并随机接受 TAVR+PCI 或 SAVR+CABG。
- 主要终点为 2 年全因死亡或致残性卒中率。
主要发现
- 需血运重建亚组中,TAVR+PCI 组 169 例,SAVR+CABG 组 163 例;非血运重建组中 TAVR 695 例,SAVR 633 例。
- TAVR+PCI 与 SAVR+CABG 的主要终点率分别为 16.0%(95%CI 11.1-22.9)与 14.0%(95%CI 9.2-21.1),P=0.62。
- 整体 TAVR 与 SAVR 的主要终点率分别为 11.9%(95%CI 9.5-14.7)与 12.3%(95%CI 9.8-15.4),P=0.76。
- 需血运重建患者较非血运重建者 STS 死亡风险评分更高(4.8±1.7% vs 4.4±1.5%,P<0.01),男性比例更高(65.1% vs 54.2%,P<0.01)。
关键数值与推荐
- 纳入标准包括中危重度主动脉瓣狭窄;排除复杂冠心病(SYNTAX 评分>22)。
- 需血运重建者 TAVR 组行 PCI,SAVR 组行 CABG。
临床怎么用
- 在中危重度主动脉瓣狭窄合并非复杂冠心病(SYNTAX≤22)患者中,可考虑 TAVR+PCI 作为 SAVR+CABG 的替代策略。
- 复杂冠心病(SYNTAX>22)患者未纳入本研究,该策略不适用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with severe aortic stenosis and coronary artery disease, the completely percutaneous approach to aortic valve replacement and revascularization has not been compared with the standard surgical approach. METHODS: The prospective SURTAVI trial (Safety and Efficiency Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement) enrolled intermediate-risk patients with severe aortic stenosis from 87 centers in the United States, Canada, and Europe between June 2012 and June 2016. Complex coronary artery disease with SYNTAX score (Synergy Between PCI with Taxus and Cardiac Surgery Trial) >22 was an exclusion criterion. Patients were stratified according to the need for revascularization and then randomly assigned to treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR). Patients assigned to revascularization in the TAVR group underwent percutaneous coronary intervention, whereas those in the SAVR group had coronary artery bypass grafting. The primary end point was the rate of all-cause mortality or disabling stroke at 2 years. RESULTS: Of 1660 subjects with attempted aortic valve implants, 332 (20%) were assigned to revascularization. They had a higher Society of Thoracic Surgeons risk score for mortality (4.8±1.7% versus 4.4±1.5%; P<0.01) and were more likely to be male (65.1% versus 54.2%; P<0.01) than the 1328 patients not assigned to revascularization. After randomization to treatment, there were 169 patients undergoing TAVR and percutaneous coronary intervention, 163 patients undergoing SAVR and coronary artery bypass grafting, 695 patients undergoing TAVR, and 633 patients undergoing SAVR. No significant difference in the rate of the primary end point was found between TAVR and percutaneous coronary intervention and SAVR and coronary artery bypass grafting (16.0%; 95% CI, 11.1-22.9 versus 14.0%; 95% CI, 9.2-21.1; P=0.62), or between TAVR and SAVR (11.9%; 95% CI, 9.5-14.7 versus 12.3%; 95% CI, 9.8-15.4; P=0.76). CONCLUSIONS: For patients at intermediate surgical risk with severe aortic stenosis and noncomplex coronary artery disease (SYNTAX score ≤22), a complete percutaneous approach of TAVR and percutaneous coronary intervention is a reasonable alternative to SAVR and coronary artery bypass grafting. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT01586910.
引用
- Søndergaard L, Popma JJ, Reardon MJ, et al. Comparison of a Complete Percutaneous Versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk: Results From the Randomized SURTAVI Trial. Circulation. 2019. PMID: 31476897. doi:10.1161/CIRCULATIONAHA.118.039564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。